CDMO and CRO Hiring Trends in 2026: What's Driving the Market Right Now

Capacity is expanding faster than talent

The single biggest hiring pressure across the CDMO sector in 2026 is the gap between physical capacity expansion and available talent. Capital investment in new manufacturing sites and modality expansions has continued at pace, particularly across biologics, cell and gene therapy, and sterile fill-finish. The specialist talent pool, though, hasn't grown at the same rate.

The result is a market where multiple CDMOs are competing for the same relatively small group of people across process development, manufacturing, quality, and technical leadership. That competition is pushing up compensation, extending hiring timelines, and placing a premium on employer positioning in ways that weren't as acute three years ago.

For CROs, the picture is similar in clinical operations, where demand for experienced global CPMs and clinical site staff continues to outpace supply across most therapeutic areas. The return of strong clinical trial volumes post-pandemic has absorbed most of the slack that existed in 2022 and 2023.

‍

Commercial hiring has become more strategic

In both CDMOs and CROs, commercial talent has moved up the strategic agenda. Boards and leadership teams are increasingly clear that growth isn't purely a manufacturing or delivery problem. It's a commercial one. Winning and retaining clients, expanding into new markets, and building relationships at the right level requires a calibre of commercial leadership that many organisations are now actively investing in for the first time.

That shift is visible in the hiring briefs. Where commercial vacancies at CDMOs once tended to focus on account management and regional BD, there's now significantly more activity at CCO, VP Commercial, and Strategic Partnerships level. CROs are seeing similar demand for proposal and bid management capability as competitive RFP processes have become more sophisticated.

‍

Cell and gene therapy continues to shape CDMO hiring

The growth of cell and gene therapy as a commercial category has created distinct hiring pressures unlike those in any other modality. The manufacturing processes are highly specialised, the regulatory environment is still developing, and the candidate pool is concentrated in a small number of geographies and institutions.

CDMOs expanding into or scaling within CGT are finding that traditional sourcing approaches don't work. Relevant candidates aren't responding to job adverts and are rarely actively looking. Reaching them requires long-term relationship building and networks that are genuinely embedded in the CGT community rather than adjacent to it.

This is an area where the gap between specialist and generalist recruitment is particularly stark. The difference between a recruiter who knows the CGT talent landscape and one who's learning it on your mandate is measured in months, and in the quality of the candidates you get in front of.

‍

Hiring timelines have lengthened at senior level

Across both sectors, lead times for senior and specialist hires have extended. A competitive market, candidates who are more cautious about making moves, and organisations running more thorough assessment processes mean that six to eight weeks from brief to offer is now more common than the three to four weeks some leadership teams still expect.

That expectation gap creates real operational problems. Organisations that start a search when a role is already critical are almost guaranteed to face a coverage gap. The CDMOs and CROs managing this well are those that have built enough forward visibility into their hiring to start searches before they become urgent, and that have strong enough relationships with specialist recruiters to move quickly when they need to.

‍

RPO and embedded talent solutions are growing

As hiring complexity has increased, more CDMOs and CROs are moving away from purely transactional recruitment relationships. The embedded RPO model, where specialist recruiters operate as an integrated part of the talent function, has grown significantly as organisations look for more consistency, accountability, and market insight than a contingency agency relationship typically provides.

The appeal is practical. You get a recruitment partner who knows your business, your culture, and your hiring standards without the cost and lead time of building an internal function. For organisations going through periods of rapid growth or significant structural change, that combination of speed, flexibility, and quality is hard to replicate any other way.

‍

→ Speak to Vector about CDMO hiring

→ Speak to Vector about CRO hiring